Faeth Therapeutics partners with Roche to evaluate PIKTOR and giredestrant in a Phase 1b/2 trial for advanced HR+/HER2-negative breast cancer.
Written By: Creola Gonsalves, MS Biotech
Reviewed By: Pharmacally Editorial Team
Faeth Therapeutics has entered into a clinical trial collaboration and supply agreement with F. Hoffmann-La Roche Ltd (Roche) to evaluate its investigational combination therapy, PIKTOR, alongside Roche’s investigational oral selective estrogen receptor degrader (SERD), giredestrant, in patients with advanced hormone receptor-positive, HER2-negative (HR+/HER2−) breast cancer.
Under the agreement, Faeth will sponsor and conduct the Phase 1b/2 study, designated FTH-PIK-101, while Roche will supply giredestrant for use in the trial. Faeth retains all commercial and intellectual property rights to PIKTOR. Financial terms and development cost-sharing arrangements were not disclosed.
The collaboration brings together two investigational approaches targeting distinct drivers of breast cancer biology: multi-node inhibition of the PI3K/AKT/mTOR signalling pathway and direct estrogen receptor degradation.
Collaboration Targets Endocrine Resistance
Activation of the PI3K/AKT/mTOR pathway is a recognised mechanism of acquired resistance to endocrine therapy in HR+/HER2− breast cancer. While single-node PI3K, AKT, and mTOR inhibitors are established options in this setting, their clinical utility can be constrained by pathway feedback loops and dose-limiting toxicities. Combining multi-node pathway suppression with a late-stage oral SERD like giredestrant offers a potential all-oral strategy to address disease progression following prior endocrine treatment.
PIKTOR Combines PI3K-alpha and mTOR Inhibition
PIKTOR is an investigational, proprietary, all-oral combination of two targeted agents: serabelisib, a selective PI3K-alpha inhibitor, and sapanisertib, a dual mTORC1/mTORC2 inhibitor.
The PI3K/AKT/mTOR signalling pathway regulates key cellular processes involved in tumour growth and survival, and its dysregulation is implicated in treatment resistance across multiple solid tumour types. By pairing PI3K-alpha inhibition with dual mTORC1/mTORC2 inhibition, PIKTOR is designed to suppress signalling at multiple points simultaneously rather than targeting a single pathway component. Its clinical benefit in combination with endocrine-directed therapies, however, remains to be established.
Phase 1b/2 Study Evaluates PIKTOR in Breast Cancer
Study FTH-PIK-101 is evaluating PIKTOR in patients with advanced HR+/HER2− breast cancer. The first patient was dosed in April 2026, and Faeth anticipates reporting interim clinical data in 2027.
The Roche collaboration introduces giredestrant as a new combination partner within the study. Faeth Chief Executive Officer Anand Parikh also indicated that the programme could potentially explore combinations involving CDK4/6 inhibitor regimens.
Faeth has previously disclosed other cohorts within the trial evaluating PIKTOR alongside fulvestrant an intramuscular SERD with or without palbociclib. Unlike those earlier cohorts, the newly announced collaboration pairs PIKTOR with an oral SERD. The November 16 announcement did not disclose detailed dosing schedules, enrolment targets, treatment arms, or primary endpoints for the giredestrant cohort.
Endometrial Cancer Programme Provides Additional Clinical Context
Alongside its breast cancer programme, Faeth is evaluating PIKTOR in combination with paclitaxel in the Phase 2 FTH-PIK-201 study in patients with advanced endometrial cancer.
On November 9, 2026, Faeth reported preliminary topline results from that study showing a confirmed objective response rate (ORR) of 33% (12 of 36 efficacy-evaluable patients) and a disease control rate of 83%, with a preliminary median progression-free survival of 7.4 months. Among patients with PIK3CA-mutated tumours, the confirmed ORR was 44% (7 of 16 patients).
While these company-reported findings provide an early clinical update on PIKTOR’s activity in a separate solid tumour setting, they do not establish the efficacy or safety of PIKTOR combined with giredestrant in breast cancer.
CEO Highlights Potential to Address Endocrine Resistance
Commenting on the agreement, Anand Parikh noted that while endocrine therapy remains the backbone of treatment for HR+/HER2− breast cancer, resistance driven by PI3K/AKT/mTOR pathway activation remains a major clinical challenge. He expressed confidence in PIKTOR’s multi-node approach and its potential application in patients whose disease has progressed on prior endocrine therapy, noting that the collaboration allows Faeth to evaluate this strategy alongside giredestrant and potentially CDK4/6-based regimens.
Reference
Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+/HER2- Advanced Breast Cancer, Faeth Therapeutics, 16 November 2026
About the Writer
Creola Gonsalves (Linkedin) is an M.S. Biotechnology postgraduate with a strong interest in clinical research, evidence interpretation, and healthcare writing, with a focus on translating life-science knowledge into meaningful real-world insights.
She is trained in Good Clinical Practice (GCP), clinical research principles, and critical interpretation of randomized clinical trials, with certifications from NIH and Stanford University.
Her research background in biotechnological applications and microbial research strengthens her ability to understand scientific evidence and develop clear, accurate, and research-driven healthcare content.
